Company news

Obsidian Therapeutics, Inc. news

Latest news releases, newest first.

Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting

October 2, 2026

Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma

August 5, 2026

Decks

Investor Presentation (August 2026)
Investor deck · 27 slides · August 2026